



DAFTAR PUSTAKA

1. Emery AEH. Population frequencies of inherited neuromuscular diseases-A world survey. *Neuromuscul Disord*. 1991;1:19–29.
2. Kim S, Zhu Y, Romitti PA, Fox DJ, Sheehan DW, Valdez R, et al. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy. *Neuromuscul Disord* [Internet]. 2017;19–22. Available from: <http://dx.doi.org/10.1016/j.nmd.2017.05.019>
3. Ruiten HJA Van, Bettolo CM, Cheetham T, Eagle M, Lochmuller H, Straub V, et al. Original article Why are some patients with Duchenne muscular dystrophy dying young : An analysis of causes of death in North East England. *Eur J Paediatr Neurol* [Internet]. 2016;20:904–9. Available from: <http://dx.doi.org/10.1016/j.ejpn.2016.07.020>
4. Suthar R, Sankhyan N. Duchenne Muscular Dystrophy : A Practice Update. *Indian J Pediatr*. 2017;
5. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy , part 1 : diagnosis , and pharmacological and psychosocial management. *Lancet Neurol* [Internet]. 2009;4422:77–93. Available from: [http://dx.doi.org/10.1016/S1474-4422\(09\)70271-6](http://dx.doi.org/10.1016/S1474-4422(09)70271-6)
6. Nascimento Osorio A, Medina Cantillo J, Camacho Salas A, Madruga Garrido M, Vilchez Padilla JJ. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. *Neurol (English Ed)* [Internet]. 2018;34:469–81. Available from: <http://dx.doi.org/10.1016/j.nrleng.2018.01.001>
7. Takeuchi F, Nakamura H, Yonemoto N, Komaki H, Rosales RL, Kornberg AJ, et al. Clinical practice with steroid therapy for Duchenne muscular dystrophy: An expert survey in Asia and Oceania. *Brain Dev* [Internet]. 2020;42:277–88. Available from: <https://doi.org/10.1016/j.braindev.2019.12.005>
8. Takeuchi F, Komaki H, Nakamura H, Yonemoto N, Kashiwabara K, Kimura E, et al. Trends in steroid therapy for Duchenne muscular dystrophy in Japan. *Muscle and Nerve*. 2016;54:673–80.
9. Iskandar K, Sunartini, Nugrahanto AP, Ilma N, Kalim AS, Adistyawan G, et al. Use of air stacking to improve pulmonary function in Indonesian Duchenne muscular dystrophy patients: Bridging the standard of care gap in low middle income country setting. *BMC Proc* [Internet]. 2019;13:1–7. Available from: <http://dx.doi.org/10.1186/s12919-019-0179-4>
10. Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy. *Neurology* [Internet]. 2014;83:529–36. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4141999/pdf/NEUROLOGY2014576256.pdf><http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=2014-32434-010&site=ehost-live%5Cnhttp://kate.bushby@ncl.ac.uk>



11. Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, et al. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. *J Pediatr* [Internet]. 2016;1–9. Available from: <http://dx.doi.org/10.1016/j.jpeds.2016.11.078>
12. Dowling JJ, Campbell C, Gonorazky HD, Cohn RD. Treating pediatric neuromuscular disorders : The future is now. 2017;1–38.
13. Wedhanto S, Siregar UP. Duchenne Muscular Dystrophy. *Maj Kedokt Indon*. 2007;57:312–7.
14. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. *J Paediatr Child Health*. 2015;1–6.
15. Wein N, Alfano L, Flanigan KM. Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. *Pediatr Clin North Am*. 2015;62:723–42.
16. Yilmaz Ö, Karaduman A, Topaloğlu H. Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. *Eur J Neurol*. 2004;11:541–4.
17. Al-Dahhak R, Kissel JT. Medical Management of Duchenne Muscular Dystrophy: In: Chamberlain JS, Rando TA, editors. Duchenne Muscular Dystrophy: Advances in Therapeutics. New York London: Taylor and Francis Inc.; 2006. p. 123–35.
18. Davis J, Samuels E, Mullins L. Nutrition Considerations in Duchenne Muscular Dystrophy. *Nutr Clin Pract*. 2015;30:511–21.
19. Matthews E, Brassington R, Kuntzer T, Jichi F, Ay M. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review). *Cochrane Database Syst Rev*. 2016;
20. Sussman MM. Duchenne Muscular Dystrophy. *J Am Acadamey Orthop Surg* [Internet]. 2002;10:138–51. Available from: http://journals.lww.com/jaaos/Abstract/2002/03000/Duchenne_Muscular_Dystrophy.9.aspx
21. Connolly AM, Florence JM, Zaidman CM, Golumbek PT, Mendell JR, Flanigan KM, et al. Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA–DMD network follow-up. *Muscle and Nerve*. 2016;54:681–9.
22. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Review Diagnosis and management of Duchenne muscular dystrophy , part 2 : implementation of multidisciplinary care. 2010;177–89.
23. Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A. Diagnosis and management of Duchenne muscular dystrophy, part 2. 2018;17:347–61.
24. Apkon SD, Alman B, Birnkrant DJ, Fitch R, Lark R, MacKenzie W, et al. Orthopedic and surgical management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 2018;142:S82–9.
25. Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional challenges in duchenne muscular dystrophy. *Nutrients*. 2017;9:1–10.



26. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy , part 1 : diagnosis , and pharmacological and psychosocial management. *Lancet Neurol* [Internet]. 2010;9:77–93. Available from: [http://dx.doi.org/10.1016/S1474-4422\(09\)70271-6](http://dx.doi.org/10.1016/S1474-4422(09)70271-6)
27. Koo T, Popplewell L, Malerba A, Dickson G. Genetic Therapy for Duchenne Muscular Dystrophy : Principles and Progress. 2004;
28. Andrews JG, Conway K, Westfield C, Trout C, Meaney FJ, Mathews K, et al. Implementation of duchenne muscular dystrophy care considerations. *Pediatrics*. 2018;142.
29. Passamano L, Taglia A, Palladino A, Viggiano E, Ambrosio PD, Scutifero M, et al. Improvement of survival in Duchenne Muscular Dystrophy : retrospective analysis of 835 patients. 2012;121–5.
30. Kieny P, Chollet S, Delalande P, Fort M Le, Magot A, Pereon Y, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. *Ann Phys Rehabil Med* [Internet]. 2013;56:443–54. Available from: <http://dx.doi.org/10.1016/j.rehab.2013.06.002>
31. Shapiro F, Zurakowski D, Bui T, Darras BT. Progression of spinal deformity in wheelchair-dependent patients with Duchenne muscular dystrophy who are not treated with steroids: Coronal plane (scoliosis) and sagittal plane (kyphosis, lordosis) deformity. *Bone Jt J*. 2014;96 B:100–5.
32. Archer JE, Gardner AC, Roper HP, Chikermane AA, Tatman AJ. Duchenne muscular dystrophy: the management of scoliosis. *J Spine Surg*. 2016;2:185–94.
33. Eliopoulos H, Laforet G, Narayana A, Lucas K, Duda P. Predictors of disease severity and progression in patients with Duchenne muscular dystrophy: A literature review. *Eur J Paediatr Neurol* [Internet]. 2017;21:e93. Available from: <http://dx.doi.org/10.1016/j.ejpn.2017.04.1208>
34. Mohammed F, Elshafey A, Al-balool H, Alaboud H, Ali MA Ben, Baqer A, et al. Mutation spectrum analysis of Duchenne/ Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine. *PLoS One*. 2018;13:1–11.
35. Buu MC. Respiratory complications, management and treatments for neuromuscular disease in children. *Curr Opin Pediatr* [Internet]. 2017;29:326–33. Available from: <http://insights.ovid.com/crossref?an=00008480-201706000-00013>
36. Liang W, Wang C, Chou P. ScienceDirect The natural history of the patients with Duchenne muscular dystrophy in Taiwan : A medical center experience. *Pediatr Neonatol* [Internet]. 2017;1–8. Available from: <http://dx.doi.org/10.1016/j.pedneo.2017.02.004>
37. Emery A. *Duchenne Muscular Dystrophy* [Internet]. second edi. Motulsky AG, Harper PS, Borrow M, Scriver C, editors. New York; 1993. 38 p. Available from: Oxford University Express



38. Sheehan DW, Birnkrant DJ, Benditt JO, Eagle M, Finder JD, Kissel J, et al. Respiratory management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 2018;142:S62–71.
39. Faysoil A, Abasse S, Silverston K. Cardiac Involvement Classification and Therapeutic Management in Patients with Duchenne Muscular Dystrophy. *J Neuromuscul Dis* [Internet]. 2017;4:17–23. Available from: <http://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/JND-160194>
40. Cheeran D, Khan S, Khera R, Bhatt A, Garg S, Grodin JL, et al. Predictors of Death in Adults With Duchenne Muscular Dystrophy–Associated Cardiomyopathy. *J Am Heart Assoc* [Internet]. 2017;6:e006340. Available from: <http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.117.006340>
41. Magliano L, Patalano M, Sagliocchi A, Scutifero M, Zaccaro A, D’angelo MG, et al. Burden, professional support, and social network in families of children and young adults with muscular dystrophies. *Muscle Nerve* [Internet]. 2015;52:13–21. Available from: <http://doi.wiley.com/10.1002/mus.24503>
42. Case LE, Apkon SD, Eagle M, Gulyas A, Juel L, Matthews D, et al. Rehabilitation management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 2018;142:S17–33.
43. Iskandar K, Dwianingsih EK, Pratiwi L, Kalim AS, Mardhiah H, Putranti AH, et al. The analysis of DMD gene deletions by multiplex PCR in Indonesian DMD/BMD patients: The era of personalized medicine. *BMC Res Notes* [Internet]. 2019;12:1–6. Available from: <https://doi.org/10.1186/s13104-019-4730-1>
44. Arias R, Andrews J, Pandya S, Pettit K, Trout C, Apkon S, et al. Palliative care services in families of males with duchenne muscular dystrophy. *Muscle Nerve* [Internet]. 2011;44:93–101. Available from: <http://doi.wiley.com/10.1002/mus.22005>
45. Andrews JG, Pandya S, Trout C, Jaff T, Matthews D, Cunniff C, et al. Palliative care services in families of males with muscular dystrophy: Data from MD STARnet. *SAGE Open Med*. 2019;7:205031211984051.
46. Varni JW, Planning U. Pediatric Quality of Life Inventory™ PedsQL.
47. Jackson CE. A Clinical Approach to Muscle Diseases. 2008;1:228–40.
48. Schmiedebergs N, Pharmacol A. HHS Public Access. 2017;94:1–23.
49. Upton P, Lawford J, Eiser C. Parent-child agreement across child health-related quality of life instruments: A review of the literature. *Qual Life Res*. 2008;17:895–913.
50. Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, et al. Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. *Eur J Heal Econ*. 2016;19–29.
51. Baiardini I, Balestracci S, Walter C, Braidò F, Rhinitis A. of Child Neurology Quality of Life in Duchenne Muscular Dystrophy: Subjective Impact on Children and Parents. 2011;



52. Deighton A, Szabo S, Salhany R, Harwood M, Mah J, Gooch K. Pro63 the Natural History of Duchenne Muscular Dystrophy in the Corticosteroid Era: a Systematic Review of Studies From Canada and the Us. *Value Heal* [Internet]. 2019;22:S852. Available from: <https://doi.org/10.1016/j.jval.2019.09.2393>
53. American Thoracic Society. Respiratory Care of the Patient with Duchenne Muscular Dystrophy. *Am J Respir Crit Care Med*. 2004;170:456–65.
54. Le Rumeur E. Dystrophin and the two related genetic diseases, duchenne and becker muscular dystrophies. *Bosn J Basic Med Sci*. 2015;15:14–20.
55. Lee T, Takeshima Y, Kusunoki N, Awano H, Yagi M, Matsuo M, et al. Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients. *J Hum Genet* [Internet]. 2014;59:46–50. Available from: <http://dx.doi.org/10.1038/jhg.2013.119>
56. Coratti G, Brogna C, Norcia G, Ricotti V, Abbott L, Amico AD, et al. Longitudinal natural history in young boys with Duchenne muscular dystrophy. *Neuromuscul Disord* [Internet]. 2019;9–14. Available from: <https://doi.org/10.1016/j.nmd.2019.09.010>
57. Aartsma-Rus A, Ginjaar IB, Bushby K. The importance of genetic diagnosis for Duchenne muscular dystrophy. *J Med Genet*. 2016;53:145–51.
58. Nascimento Osorio A, Medina Cantillo J, Camacho Salas A, Madruga Garrido M, Vilchez Padilla JJ. Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. *Neurol (English Ed)* [Internet]. 2019;34:469–81. Available from: <http://dx.doi.org/10.1016/j.nrleng.2018.01.001>
59. Toussaint M, Pernet K, Steens M, Haan J, Sheers N. Cough augmentation in subjects with duchenne muscular dystrophy: Comparison of air stacking via a resuscitator bag versus mechanical ventilation. *Respir Care*. 2016;61:61–7.
60. Buddhe S, Cripe L, Friedland-Little J, Kertesz N, Eghtesady P, Finder J, et al. Cardiac management of the patient with Duchenne muscular dystrophy. *Pediatrics*. 2018;142:S99–106.
61. Mavrogeni SI, Markousis-Mavrogenis G, Papavasiliou A, Papadopoulos G, Kolovou G. Duchenne Muscular Dystrophy: Methods and Protocols, Methods in Molecular Biology. In: Bernadini C, editor. *Cardiac Involvement in Duchenne Muscular Dystrophy and Related Dystrophinopathies*. Springer Science + Business Media; 2018. p. 31.
62. Cheuk DKL, Wong V, Wraige E, Baxter P, Cole A. Surgery for scoliosis in Duchenne muscular dystrophy. *Cochrane Database Syst Rev*. 2015;2015.
63. Bachrach LK. Taking steps towards reducing osteoporosis in Duchenne muscular dystrophy. *Neuromuscul Disord*. 2005;15:86–7.
64. Farrar M, Perera N. Bone Health in Children with Duchenne Muscular Dystrophy: A Review. *Pediatr Ther*. 2015;05:252.
65. Gauld LM, Kappers J, Carlin JB, Robertson CF. Height prediction from ulna length. *Dev Med Child Neurol*. 2004;46:475–80.



66. Davidson ZE, Mazala D, Truby H, Grange R. Regenerative Medicine for Degenerative Muscle Disease, Stem Cell Biology and Regenerative Medicine. In: Practical Nutrition Guidelines for Individuals with Duschenne Muscular Dystrophy. M.K.Childe. New York: Springer Science + Business Media; 2016. p. 225.
67. Bell KL, Davies PSW, Boyd RN, Stevenson RD. Use of Segmental Lengths for the Assesment of Growth in Children with Cerebral Palsy. *Handb Anthr Phys Meas Hum Form Heal Dis*. 2012;1279.
68. Griffith R, Edwards R. A new chart for weight control in Duschenne muscular dystrophy. *Arch Dis Child*. 1988;1256–8.
69. Davidson ZE, Truby H. A review of nutrition in Duchenne muscular dystrophy. *J Hum Nutr Diet*. 2009;22:383–93.
70. Matthews E, Brassington R, Kuntzer T, Jichi F, Ay M. Corticosteroids for the treatment of Duchenne muscular dystrophy (Review) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. *Cochrane Database Syst Rev*. 2016;
71. Darras BT, Urion DK, Ghosh PS. Corticosteroid Therapy in DMD. *Dystrophinopathies Gene Rev*. 2018;
72. McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. *Lancet*. 2018;391:451–61.